Inhibition of severe acute respiratory syndrome coronavirus replication by niclosamide.
Antiviral agents are urgently needed to fight severe acute respiratory syndrome (SARS). We showed that niclosamide, an existing antihelminthic drug, was able to inhibit replication of a newly discovered coronavirus, SARS-CoV; viral antigen synthesis was totally abolished at a niclosamide concentration of 1.56 microM, as revealed by immunoblot analysis. Thus, niclosamide represents a promising drug candidate for the effective treatment of SARS-CoV infection.
Wu
Chang-Jer
CJ
Institute of Preventive Medicine, National Defense Medical College, National Defense University, Taipei, Taiwan.
Jan
Jia-Tsrong
JT
Chen
Chi-Min
CM
Hsieh
Hsing-Pang
HP
Hwang
Der-Ren
DR
Liu
Hwan-Wun
HW
Liu
Chiu-Yi
CY
Huang
Hui-Wen
HW
Chen
Su-Chin
SC
Hong
Cheng-Fong
CF
Lin
Ren-Kuo
RK
Chao
Yu-Sheng
YS
Hsu
John T A
JT
D000818:Animals; D000871:Anthelmintics / Q000494:pharmacology*; D000998:Antiviral Agents; D002522:Chlorocebus aethiops; D005455:Fluorescent Antibody Technique; D009534:Niclosamide / Q000494:pharmacology*; D045473:Severe acute respiratory syndrome-related coronavirus / Q000187:drug effects*; D014709:Vero Cells; D014779:Virus Replication / Q000187:drug effects*
D000871:Anthelmintics; D000998:Antiviral Agents; D009534:Niclosamide